The stock of Arbutus Biopharma Corporation (NASDAQ:ABUS) increased by $0.01 on Wednesday to $2.00, up 0.25 percent. The last five days have seen an average of 604,189 shares of common stock traded. 18 times new highs were reached in the current year, with a fall of -$0.3300. The average number of shares traded over the last 20 days was 524,637, while the average volume over the last 50 days totaled 608,919.
ABUS stock dropped -9.73% since last month. On 08/14/23, the company’s shares reached a one-month low of $1.9845. The stock touched a high of $3.14 on 03/30/23, after rallying from a low of $1.85 in 52 weeks. The price of ABUS stock has declined by -14.38% or -$0.3300 this year, reaching a new high 18 times. Still, the stock price is down -36.57% from the 52-week high.
Valuation Metrics
Beta for the stock is 2.13. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 14.37, the price-to-book (PB) ratio of 2.46.
Financial Health
For the three months ended June 29, Arbutus Biopharma Corporation’s quick ratio was 6.50, while its current ratio was 6.50, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $104.47 million and revenue of $39.02 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ABUS’s return on assets (ROA) during the last 12 months has been -38.00%. There was a -51.10% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -52.00%.
Earnings Surprise
According to Arbutus Biopharma Corporation’s quarterly financial report for the quarter that ended June 29, it had $125.29 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $4.65 million, while revenues fell by -206.24% to $6.69 million. It was predicted that Arbutus Biopharma Corporation’s quarterly earnings would be -$0.1, but it ended up being -$0.11, beating the consensus by 9.10%. EBITDA was -$18.04 million for the quarter. At the end of Arbutus Biopharma Corporation’s most recent quarter ended June 29, its liabilities totaled 42.13 million, while its total debt was $2.04 million.
Technical Picture
Here’s a quick look at Arbutus Biopharma Corporation’s (ABUS) price momentum from a technical perspective. As of 15 August, the RSI 9-day stood at 32.15%, suggesting the stock is Neutral, with a 31.26% historical volatility rate.
The stochastic %K and %D were 6.87% and 13.09% respectively, while the average true range (ATR) was 0.0656. Based on the 14-day stochastic reading of 6.87%, the RSI (14) reading is 33.34%. On the 9-day MACD Oscillator, the stock is at -0.0444, and the 14-day reading is at -0.0757.
Analyst Ratings
In its most recent analyst report, Jefferies raised its rating on Arbutus Biopharma Corporation (NASDAQ: ABUS) to a Buy. Prior to this, analysts firm rated the stock as a Hold. Analysts have assigned Arbutus Biopharma Corporation (ABUS) an Buy rating. ABUS is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.
What is ABUS’s price target for the next 12 months?
The current consensus forecast for the stock is between $4.00 and $6.00, with a median target price of $6.00. In analyzing these forecasts, the average price target given by analysts for Arbutus Biopharma Corporation (ABUS) is $5.40.
